Condition: SARS CoV-2 Post-Acute Sequelae · Sponsor: Mount Sinai Hospital, Canada
The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.
This description comes directly from the study's public registry record.
Dr. Kieran Quinn · 416-843-8403 · kieran.quinn@mail.utoronto.ca
Always discuss trial participation with your own doctor first.
| Kingston Health Sciences Centre | Kingston, Ontario, Canada | Not Yet Recruiting |
| Niagara Health System | St. Catharines, Ontario, Canada | Not Yet Recruiting |
| Mount Sinai Hospital, Sinai Health System | Toronto, Ontario, Canada | Recruiting |
| St. Joseph's Health Centre, Unity Health Toronto | Toronto, Ontario, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06792214